Standard BioTools (LAB) to Release Quarterly Earnings on Wednesday

Standard BioTools (NASDAQ:LAB) is expected to be announcing its earnings results after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $43.03 million for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Standard BioTools Stock Performance

NASDAQ:LAB opened at $1.30 on Monday. The firm has a market cap of $483.94 million, a PE ratio of -1.83 and a beta of 1.57. Standard BioTools has a fifty-two week low of $1.17 and a fifty-two week high of $3.04. The business has a 50 day moving average price of $1.68 and a 200-day moving average price of $1.81.

Wall Street Analysts Forecast Growth

Separately, TD Cowen dropped their price objective on Standard BioTools from $2.75 to $2.50 and set a “buy” rating for the company in a research note on Thursday, October 31st.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.